# Charlie's Holdings, Inc.: overview CHUC · OTC · CIK 1134765 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/chuc.md) · [Financials](/companies/chuc/financials.md) · [Filings](/companies/chuc/filings.md) · [Insiders](/companies/chuc/insiders.md) Latest reported revenue: [$3.8m](/filings/0001437749-26-028182.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 17, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001437749-26-028182). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [1,624](/filings/0001437749-25-035731.md) | [1,047 d](/filings/0001437749-26-010761.md) | [1,578](/filings/0001437749-26-017948.md) | [1,761](/filings/0001437749-26-028182.md) | [7,084](/filings/0001437749-25-035731.md) | [8,982 d](/filings/0001437749-26-010761.md) | [4,804](/filings/0001437749-26-017948.md) | [3,802](/filings/0001437749-26-028182.md) | | Gross margin | % | [38.8%](/filings/0001437749-25-035731.md) | [50.1% d](/filings/0001437749-26-010761.md) | [24.5%](/filings/0001437749-26-017948.md) | [27.6%](/filings/0001437749-26-028182.md) | [24.9%](/filings/0001437749-25-035731.md) | [30.1% d](/filings/0001437749-26-010761.md) | [24.6%](/filings/0001437749-26-017948.md) | [29.4%](/filings/0001437749-26-028182.md) | | Operating margin | % | [(53.9%)](/filings/0001437749-25-035731.md) | [(71.7%) d](/filings/0001437749-26-010761.md) | [(55.7%)](/filings/0001437749-26-017948.md) | [(54.2%)](/filings/0001437749-26-028182.md) | [(4.8%)](/filings/0001437749-25-035731.md) | [(1.4%) d](/filings/0001437749-26-010761.md) | [(20.3%)](/filings/0001437749-26-017948.md) | [(32.5%)](/filings/0001437749-26-028182.md) | | Net margin | % | [(62.9%)](/filings/0001437749-25-035731.md) | [(107.4%) d](/filings/0001437749-26-010761.md) | [(77.1%)](/filings/0001437749-26-017948.md) | [281.7%](/filings/0001437749-26-028182.md) | [8.8%](/filings/0001437749-25-035731.md) | [1.5% d](/filings/0001437749-26-010761.md) | [(21.9%)](/filings/0001437749-26-017948.md) | [(43.7%)](/filings/0001437749-26-028182.md) | | Diluted EPS | $ per share | [0.00](/filings/0001437749-25-035731.md) | not reported | [0.00](/filings/0001437749-25-021440.md) | [0.00](/filings/0001437749-25-035731.md) | [0.00](/filings/0001437749-25-035731.md) | not reported | not reported | not reported | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [21.5](/filings/0001437749-23-010449.md) | [26.4](/filings/0001437749-24-012061.md) | [16.3](/filings/0001437749-24-012061.md) | [7.8](/filings/0001437749-26-010761.md) | [20.9](/filings/0001437749-26-010761.md) | | Gross margin | % | not reported | not reported | not reported | [37.1%](/filings/0001437749-26-010761.md) | [27.0%](/filings/0001437749-26-010761.md) | | Operating margin | % | [2.6%](/filings/0001437749-23-010449.md) | [(6.8%)](/filings/0001437749-24-012061.md) | [(13.6%)](/filings/0001437749-25-018798.md) | [(42.5%)](/filings/0001437749-26-010761.md) | [(10.4%)](/filings/0001437749-26-010761.md) | | Net margin | % | [22.4%](/filings/0001437749-23-010449.md) | [(6.0%)](/filings/0001437749-24-012061.md) | [(12.9%)](/filings/0001437749-25-018798.md) | [(53.6%)](/filings/0001437749-26-010761.md) | [21.5%](/filings/0001437749-26-010761.md) | | Diluted EPS | $ per share | [0.01](/filings/0001437749-23-010449.md) | [(0.01)](/filings/0001437749-24-012061.md) | [(0.01)](/filings/0001437749-25-018798.md) | [(0.02)](/filings/0001437749-26-010761.md) | [0.02](/filings/0001437749-26-010761.md) | | Free cash flow | $m | [(1.5)](/filings/0001437749-23-010449.md) | [(1.9)](/filings/0001437749-24-012061.md) | [(0.8)](/filings/0001437749-25-018798.md) | [(1.6)](/filings/0001437749-26-010761.md) | [(5.8)](/filings/0001437749-26-010761.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:Revenues; Gross profit: us-gaap:GrossProfit. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/chuc/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Ascentis Wealth Management, LLC](/funds/2032602.md) | 2026-06-30 | $194 | 923 | | Unchanged | ## Recent filings [All 591 filings](/companies/chuc/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-17 | 16:16 ET | [10-Q](/filings/0001437749-26-028182.md) | Quarterly report, period 2026-06-30 | 0001437749-26-028182 | | 2026-08-04 | 17:24 ET | [8-K](/filings/0001437749-26-025735.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-025735 | | 2026-06-05 | 16:31 ET | [8-K](/filings/0001437749-26-019751.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001437749-26-019751 | | 2026-05-21 | 18:34 ET | [8-K](/filings/0001437749-26-017985.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001437749-26-017985 | | 2026-05-20 | 16:15 ET | [10-Q](/filings/0001437749-26-017948.md) | Quarterly report, period 2026-03-31 | 0001437749-26-017948 | | 2026-04-20 | 16:30 ET | [DEF 14A](/filings/0001437749-26-012836.md) | Proxy statement, period 2026-06-04 | 0001437749-26-012836 | | 2026-04-01 | 18:35 ET | [10-K](/filings/0001437749-26-010761.md) | Annual report, period 2025-12-31 | 0001437749-26-010761 | | 2026-02-13 | 17:16 ET | [8-K](/filings/0001437749-26-004180.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001437749-26-004180 | | 2025-11-19 | 16:16 ET | [10-Q](/filings/0001437749-25-035731.md) | Quarterly report, period 2025-09-30 | 0001437749-25-035731 | | 2025-08-21 | 07:30 ET | [10-Q](/filings/0001437749-25-027482.md) | Quarterly report, period 2025-06-30 | 0001437749-25-027482 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-010761.md), filed Apr 1, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/2d506d02-ce7e-48db-a4c1-425143cc7aac) ## About the filer - CIK: 1134765 - Tickers: CHUC - Exchange: OTC - SIC code: 2833 Medicinal Chemicals & Botanical Products - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.